96 results
S-1
GLYC
GlycoMimetics Inc
4 Oct 13
IPO registration
12:00am
are employed by the Company itself and will be utilized in the development of the drug candidate through NDA.
Nature and type of product – The drug … and proprietary nature of the license, the Company believes that its R&D services could not reasonably be performed by Pfizer. The Company believes
CORRESP
GLYC
GlycoMimetics Inc
23 Oct 13
Correspondence with SEC
12:00am
revise your disclosure regarding aggregated milestones to disclose the nature of the various milestone triggering events for each aggregated category … , and the achievement of any milestone is highly contingent on a number of factors, most of which, by the nature of drug discovery, are not within
8-K
EX-10.1
GLYC
GlycoMimetics Inc
28 Jul 14
Entry into a Material Definitive Agreement
12:00am
detail the nature and extent of any requested Tenant Changes.
4.4.2 All Tenant Change Requests shall be subject to Landlord’s prior written approval … the same form as the AIA standard change order form (a “Landlord Change Request”), which Landlord Change Request shall detail the nature and extent of any
10-K
EX-10.19
5k1fefmo4qn54o4oxv
31 Mar 14
Annual report
12:00am
S-1
EX-10.4
3cgbntb03mew2of79qg
4 Oct 13
IPO registration
12:00am
S-1
EX-10.3
100engn
4 Oct 13
IPO registration
12:00am
CORRESP
5w4ql
18 Oct 13
Correspondence with SEC
12:00am
S-1
EX-10.2
dytj1siope2c4mnf
4 Oct 13
IPO registration
12:00am
D/A
7kto6vj0n2h9ti15xv26
27 Oct 10
$50M in equity / securities to be acquired, sold $38.98M, 15 investors
12:00am
8-K
EX-99.1
556wxlhpcvbgomkii6bq
2 May 19
Glycomimetics Reports First Quarter 2019 Results
8:30am
D
cbcbtzfz 87
4 Nov 09
$15.32M in equity / debt / options / securities to be acquired, sold $15.32M, 10 investors
12:00am